Welcome to our dedicated page for Radius Health news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Health stock.
Radius Recycling, Inc. (formerly Schnitzer Steel Industries, Inc.) has been a frequent subject of corporate, financial, and transaction-related news due to its role in metals recycling and steel manufacturing and its transition from a public company to a wholly owned subsidiary of Toyota Tsusho America, Inc. News coverage for the former Nasdaq-listed symbol RDUS includes quarterly and annual financial results, operating updates, and major corporate events.
Company earnings releases have provided details on ferrous and nonferrous sales volumes, finished steel volumes, average net selling prices, rolling mill utilization, and adjusted EBITDA. These reports explain how changes in global ferrous and finished steel prices, nonferrous demand, scrap availability, and productivity initiatives have affected margins and profitability. They also highlight the company’s cost reduction and productivity programs, investments in advanced metal recovery technologies, and expansion of its recycling services platform.
News items have also covered governance and leadership developments, such as the appointment of a chief operating officer and new board members, reflecting ongoing attention to operational performance and strategic direction. In addition, Radius has regularly announced quarterly cash dividends, noting a long history of paying dividends since its initial public offering.
A major focus of recent news has been the definitive merger agreement under which Toyota Tsusho America, Inc. agreed to acquire Radius Recycling, Inc. Press releases and subsequent SEC filings describe the agreed cash consideration for Radius shareholders, the rationale for combining the businesses, and the expectation that Radius would continue to operate from its Portland, Oregon headquarters with its brands and facilities retained. Later news documented the receipt of required regulatory approvals, shareholder approval, and the closing of the merger.
Following completion of the transaction and the delisting and deregistration of RDUS, this news page functions as an archive of historical announcements, financial updates, and corporate actions related to Radius Recycling, Inc. during its period as a publicly traded company.
Radius Health (Nasdaq: RDUS) will announce its second quarter financial results on August 10, 2020, followed by a conference call at 8:30 a.m. ET. The event will offer insights into the company’s financial performance and future strategies. A replay will be available later the same day. Radius specializes in endocrine therapeutics, with notable products like TYMLOS for osteoporosis, and has a growing pipeline that includes investigational drugs for various conditions.
Radius Health has entered a global licensing agreement with Menarini for elacestrant, an oral selective estrogen receptor degrader, currently in late-stage Phase 3 development for advanced ER+/HER2- breast cancer. This deal includes a $30 million upfront payment and potential up to $320 million in milestone payments, plus tiered royalties on sales. Radius will continue to manage the EMERALD Phase 3 study, which involves about 460 patients. The partnership strengthens Menarini's oncology portfolio and provides Radius with financial flexibility for future initiatives.
Summary not available.